Search Results

8 results

  1. CORESTA Congress, Kunming, 2018, Agronomy/Phytopathology Groups, APPOST 11

    Field trials with low nicotine tobacco varieties developed by conventional breeding technique: first results

    MALPICA A.(1); EVANS W.(2); ARCHIBALD C.(3); SCOTT L.(4); GARWE D.(5); CHAMANGO A.M.Z.(6); DORLHAC de BORNE F.(7); COLARD S.(8)
    (1) Bergerac Seed and Breeding, Bergerac, France; (2) Imperial Tobacco South Africa Pvt. Ltd, Umhlanga, Durban, South Africa; (3) Alliance One International Services, Camberley, Surrey, U.K.; (4) Universal Leaf Tobacco Co., Richmond, VA, U.S.A.; (5) Tobacco Research Board (TRB), Harare, Zimbabwe; (6) Agricultural Research & Extension Trust (ARET), Lilongwe, Malawi; (7) Imperial Tobacco Limited, Bergerac, France; (8) SEITA - Imperial Brands plc, Paris, France
    In 2015, the World Health Organisation (WHO) Study Group on Tobacco Product Regulation (“TobReg”) issued an advisory note recommending a strategy of reducing nicotine in tobacco to substantially lower levels of 0.4 mg/g. In the U.S., the Food and Drug ...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 21

    The use of in vitro human biomarkers from relevant primary cell lines, to assess the effects of increasing nicotine concentration in e-liquids

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); BERG E.(2); WALELE T.(3)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) DiscoverX Corporation, Fremont, CA, U.S.A.; (3) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    As part of the ongoing stewardship of electronic cigarettes, and in line with the National Academies of Sciences “ Toxicity Testing in the 21st Century: A Vision and a Strategy ”, Fontem Ventures B.V. have investigated the utility of a series of endpoints ...
  3. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, ST 48

    The proposed use of human cells to cover the ‘R’ end point for EUTPD2 data requirements from a 21st century toxicology perspective

    SIMMS L.(1); PALMER J.(2)
    (1) Imperial Tobacco Limited, Bristol, U.K.; (2) Stemina, Madison, WI, U.S.A.
    In 2007 the National Academies of Sciences released “Toxicity Testing in the 21st Century: A Vision and a Strategy”, a new toxicological paradigm, moving away from the idea of high dose animal tests as the ‘gold standard’ and focusing on the use of human ...
  4. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, STPOST 26

    A review of aerosol exposure systems relative to the analysis of cytotoxicity: a CORESTA In vitro Toxicity Testing Sub-Group perspective

    THORNE D.(1); WIECZOREK R.(2); FUKUSHIMA T.(3); SHIN H.J.(4); LEVERETTE R.(5); BALLANTYNE M.(6); LI X.(7); BOMBICK B.(5)
    (1) British American Tobacco, R&D Centre, Southampton, U.K.; (2) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (3) Japan Tobacco Inc., Scientific Product Assessment Centre, Yokohama, Kanagawa, Japan; (4) KT&G Corporation, Daejeon, South Korea; (5) RAI Services Company, Winston-Salem, NC, U.S.A.; (6) Covance Laboratories Ltd, Harrogate, U.K.; (7) Zhengzhou Tobacco Research Institute of CNTC, Zhengzhou, P.R. China
    Aerosol exposure systems offer researchers a variety of ways to customise the exposure set-up, modify experimental parameters and provide a novel and versatile platform for in vitro aerosol research. These systems produce an aerosol that more closely ...
  5. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, STPOST 32

    Cellular transformation activity of different tobacco condensates in the Bhas 42 cell assay

    STEVENSON M.(1); WIECZOREK R.(2); SIMMS L.(1); PANT K.(3)
    (1) Imperial Tobacco Limited, Bristol, U.K.; (2) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (3) BioReliance, Sigma-Aldrich Corp., Rockville, MD, U.S.A.
    Carcinogenesis has been described as a multi-stage process comprising of initiation, promotion and progression. Smoking is a cause of serious disease in smokers, including lung cancer. Determining the carcinogenic potential of a tobacco product ingredient ...
  6. Tob. Sci., 1992, 36, p. 8-9., ISSN.0082-4623.

    Species composition of parasitoids of the tobacco aphid, Myzus nicotianae Blackman (Homoptera: Aphididae) in Eastern Tennessee

    SONG J.; PLESS C.D.; MILLER R.D.
    University of Florida, Dept. of Entomology and Nematology, Gainesville, FL, USA.
    The tobacco aphid, Myzus nicotianae Blackman, was commonly parasitized on tobacco plants, Nicotiana tabacum L., in greenhouses but rarely in the field. Five species of primary hymenopteran parasitoids were collected from greenhouses; only one primary ...